secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001104659-24-115052
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood Q3 revenue down 19% YoY to $91.6M; LINZESS Rx demand +13%
------------------------------------------------------------------

- GAAP net income $3.6M ($0.02 diluted EPS) vs $15.3M ($0.10) a year ago.
- Total revenue $91.6M, down from $113.7M in Q3 2023; cites pricing headwinds.
- LINZESS new-to-brand and extended-unit prescriptions each grew 13% YoY.
- Apraglutide NDA submission for short bowel syndrome on track for Q1 2025.
- Full-year 2024 financial guidance reaffirmed; Adjusted EBITDA $26.2M vs $49.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465924115052/0001104659-24-115052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465924115052/tm2427582d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-115052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer